Refine
Document Type
- Article (4)
Language
- English (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- biomarker (1)
- everolimus (1)
- metastatic renal cell carcinoma (1)
- phase IV (1)
- second-line (1)
We investigate the possibility that high-energy photons are channeled, when passing through an oriented single crystal, due to Delbrück scattering. For this purpose the exact electron propagator for the single-string model is constructed. Starting from a separation of variables, we solve the Dirac equation for a cylindrical electrostatic potential. The propagator for such external fields is constructed from solutions of the radial Dirac equation. This propagator is applied to a calculation of the S matrix for Delbrück scattering. We specify the conditions under which photon channeling takes place. Unfortunately these conditions are only matched for a very small fraction of those photons being produced by channeled electrons.
An alternative theoretical description of axial electron channeling in the multi-GeV region has been developed. We solve a kinetic equation to evaluate an electron distribution function in axially oriented single crystals. Based on the single-string model, the required matrix elements for radiation and scattering by lattice vibrations are calculated employing solutions of the Dirac equation in cylindrical coordinates. Results obtained for 150-GeV electrons propagating along the <110> axis of germanium are in good agreement with experimental observations.
The magnetic dipole scattering of neutrinos by the electrostatic potentials of single atoms as well as crystals is investigated. It is shown that scattering by a rigid cubic lattice can amplify the neutrino-atom cross section by a factor of N1/3, N being the number of scatterers. However, comparing the results with typical weak-interaction cross sections, the effect seems to be not observable in experiment.
Simple Summary: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after failure of one prior tumor therapy. In an exploratory approach, predictive blood biomarkers were searched. We found lower levels of the protein thrombospondin-2 (TSP-2) at the start of the therapy and higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation to be associated with therapy response. Of note, these blood biomarkers had a higher predictive value than baseline patient parameters or risk classifications. Polymorphisms in the mTOR gene appeared to be associated with therapy response, but were not significant. To conclude, it seems feasible to identify patients showing longtime responses to everolimus and possible to increase tumor therapy response rates based on biomarkers for individual therapy selection.
Abstract: There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8, p = 0.005). Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013) and improved overall survival (OS; 31.0 months vs. 14.0 months, p < 0.001). Baseline TSP-2 levels had a stronger relation to PFS (HR 0.36, p = 0.008) than baseline patient parameters, including IMDC score. Increased serum LDH levels two weeks after therapy initiation were the best predictor for OS (HR 0.21, p < 0.001). mTOR polymorphisms appeared to be associated with therapy response but were not significant. Hence, we identified TSP-2 and LDH as promising predictive biomarkers for therapy response on everolimus after failure of one VEGF-targeted therapy in patients with clear cell mRCC.
